During the last session, IN8bio Inc (NASDAQ:INAB)’s traded shares were 0.28 million, with the beta value of the company hitting -0.05. The 52-week high for the INAB share is $2.48, that puts it down -978.26 from that peak though still a striking 4.35% gain since the share price plummeted to a 52-week low of $0.22. The company’s market capitalization is $10.53M, and the average intraday trading volume over the past 10 days was 0.42 million shares, and the average trade volume was 273.43K shares over the past three months.
IN8bio Inc (INAB) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.00. INAB has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.16.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
IN8bio Inc (NASDAQ:INAB) trade information
IN8bio Inc (INAB) registered a -2.09% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -2.09% in intraday trading to $0.23, hitting a weekly high. The stock’s 5-day price performance is -14.51%, and it has moved by -25.27% in 30 days. Based on these gigs, the overall price performance for the year is -77.49%. The short interest in IN8bio Inc (NASDAQ:INAB) is 0.18 million shares and it means that shorts have 0.44 day(s) to cover.
IN8bio Inc (INAB) estimates and forecasts
Statistics show that IN8bio Inc has outperformed its competitors in share price, compared to the industry in which it operates. IN8bio Inc (INAB) shares have gone down -79.72% during the last six months, with a year-to-date growth rate more than the industry average at 35.00% against 17.50. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 30.40% this quarter and then jump 57.10% in the quarter after that.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -50.62%. While earnings are projected to return 42.00% in 2024.
INAB Dividends
IN8bio Inc is due to release its next quarterly earnings on 2024-Aug-08. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
IN8bio Inc (NASDAQ:INAB)’s Major holders
IN8bio Inc insiders own 21.56% of total outstanding shares while institutional holders control 45.94%, with the float percentage being 58.57%. AIGH CAPITAL MANAGEMENT LLC is the largest shareholder of the company, while 29.0 institutions own stock in it. As of 2024-06-30, the company held over 2.13 million shares (or 4.9157% of all shares), a total value of $1.8 million in shares.
The next largest institutional holding, with 1.42 million shares, is of VANGUARD GROUP INC’s that is approximately 3.2892% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $1.21 million.
